Published on
August 4, 2017
- 10:30 GMT
Epizyme Reports Second Quarter 2017 Financial Results and Clinical and Business Progress
Key Clinical Milestones Achieved in Studies of Mesothelioma, Epithelioid Sarcoma and Pediatric Solid Tumors Expansion of Collaborations to Accelerate Investigation of Tazemetostat Across Multiple Tumor Types Conference Call to be Held Today at 8:00 a.m. ET …
Distribution channels:
Banking, Finance & Investment Industry, Technology
